Targeting HNF4α could affect multiple nuclear receptors beyond the HNF4α-PPARα axis, potentially improving sepsis-associated hepatic steatosis, cholestasis, apoptosis, and alterations in drug metabolism. The gene discussed is PPARA; the disease is cholestasis.